Skip to main content
Erschienen in: Aesthetic Plastic Surgery 2/2021

18.12.2019 | Original Article

The Efficacy of Drug Injection in the Treatment of Pathological Scar: A Network Meta-analysis

verfasst von: Pengfei Sun, Xiaosheng Lu, Huachang Zhang, Zhensheng Hu

Erschienen in: Aesthetic Plastic Surgery | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Pathological scars mainly include hyperplastic scars and keloids, and there is no uniform treatment standard for the treatment of pathological scar in clinic now. Drug injection in the treatment of pathological scar is widely used because of its advantages of less trauma and simple operation. Therefore, we used a network meta-analysis to compare the curative effect of four kinds of drugs which are commonly used in the treatment of pathological scar such as botulinum toxin type A, corticosteroids (including diprospan and triamcinolone acetonide (TAC)), verapamil and 5-fluorouracil (5-FU), systematically. It is hoped that our study will provide evidence for the choice of drugs in the treatment of pathological scar by injection.

Methods

Relevant articles from Wanfang, VIP, CNKI, PubMed, Cochrane Library and Embase databases were extracted by us. They were included into a network meta-analysis to compare the four kinds of drugs which are commonly used in the treatment of pathological scar.

Results

The network meta-analysis included a total of 1513 patients from 23 studies. Through meta-analysis, we found that the efficacy of botulinum toxin type A combined with corticosteroid drugs was best in the treatment of pathological scar by injection. There was no significant difference between botulinum toxin type A, corticosteroids combined with 5 Fu, verapamil and 5-FU. The efficacy of corticosteroids combined with 5-FU was better than that of corticosteroids alone and verapamil alone, but there was no significant difference between them and 5-FU. Further, the order of efficacy predicted by the SUCRA curve was as follows: botulinum toxin type A combined with corticosteroids > corticosteroids combined with 5-FU > botulinum toxin type A > corticosteroids > 5-FU > verapamil. Moreover, no publication bias was found in the funnel diagram.

Conclusion

In the injection treatment of pathological scar, we recommend the combined injection of two drugs, especially botulinum toxin type A combined with corticosteroids. The effective treatment of botulinum toxin type A combined with corticosteroids in the treatment of pathological scar is as follows: Patients were treated once monthly with intralesional injection of TAC (0.1 ml/cm3) mixed with botulinum toxin type A (2.5 IU/cm3) for a total of 3 treatments. However, there are still limitations in this network meta-analysis, and its conclusion still needs to be further confirmed by more randomized controlled trials.

Level of Evidence III

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.​springer.​com/​00266.
Literatur
1.
Zurück zum Zitat Trisliana Perdanasari A, Torresetti M, Grassetti L et al (2015) Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burns Traum 3:14CrossRef Trisliana Perdanasari A, Torresetti M, Grassetti L et al (2015) Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burns Traum 3:14CrossRef
2.
Zurück zum Zitat Morelli Coppola M, Salzillo R, Segreto F et al (2018) Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol 11:387–396PubMedPubMedCentralCrossRef Morelli Coppola M, Salzillo R, Segreto F et al (2018) Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol 11:387–396PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Trisliana Perdanasari A, Lazzeri D, Su W et al (2014) Recent developments in the use of intralesional injections keloid treatment. Arch Plast Surg 41(6):620–629PubMedPubMedCentralCrossRef Trisliana Perdanasari A, Lazzeri D, Su W et al (2014) Recent developments in the use of intralesional injections keloid treatment. Arch Plast Surg 41(6):620–629PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Berman B, Maderal A, Raphael B (2017) Keloids and Hypertrophic Scars: pathophysiology, Classification, and Treatment. Dermatol Surg 43(Suppl 1):S3–S18PubMedCrossRef Berman B, Maderal A, Raphael B (2017) Keloids and Hypertrophic Scars: pathophysiology, Classification, and Treatment. Dermatol Surg 43(Suppl 1):S3–S18PubMedCrossRef
5.
Zurück zum Zitat Poetschke J, Gauglitz GG (2016) Current options for the treatment of pathological scarring. J Dtsch Dermatol Ges 14(5):467–477PubMed Poetschke J, Gauglitz GG (2016) Current options for the treatment of pathological scarring. J Dtsch Dermatol Ges 14(5):467–477PubMed
6.
Zurück zum Zitat Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784CrossRef Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784CrossRef
7.
Zurück zum Zitat Zhao Y, Shen L (2016) Application of botulinum toxin type A in the treatment of intractable pain and itching of keloid. Chin J Woman Child Health Res S2:54–55 Zhao Y, Shen L (2016) Application of botulinum toxin type A in the treatment of intractable pain and itching of keloid. Chin J Woman Child Health Res S2:54–55
8.
Zurück zum Zitat Zhang Z, Chen J, Xia Jianbing J (2017) A clinical study of the injection of botulinum toxin A in the treatment of scar tissue. China Med Cosmetol 09:19–21 Zhang Z, Chen J, Xia Jianbing J (2017) A clinical study of the injection of botulinum toxin A in the treatment of scar tissue. China Med Cosmetol 09:19–21
9.
Zurück zum Zitat Wang L, Ta N, M Fu et al (2009) Botulinum toxin type A for the treatment of keloid with obstinate pain and itch. J Tissue Eng Reconstr Surg 05:286–288 Wang L, Ta N, M Fu et al (2009) Botulinum toxin type A for the treatment of keloid with obstinate pain and itch. J Tissue Eng Reconstr Surg 05:286–288
10.
Zurück zum Zitat Liu B, Li J, Hu H (2017) Efficacy and safety of botulinum toxin type A on scar treatment. Chin J Dermatovenereol Integr Tradit West Med 01:25–27 Liu B, Li J, Hu H (2017) Efficacy and safety of botulinum toxin type A on scar treatment. Chin J Dermatovenereol Integr Tradit West Med 01:25–27
11.
Zurück zum Zitat Cheng P (2015) Botulinum toxin A joint Qu An Ned clinical observation for the treatment of hyperplastic scar. J Taishan Med Coll 04:390–392 Cheng P (2015) Botulinum toxin A joint Qu An Ned clinical observation for the treatment of hyperplastic scar. J Taishan Med Coll 04:390–392
12.
Zurück zum Zitat Aggarwal A, Ravikumar BC, Vinay KN et al (2018) A comparative study of various modalities in the treatment of keloids. Int J Dermatol 57(10):1192–1200PubMedCrossRef Aggarwal A, Ravikumar BC, Vinay KN et al (2018) A comparative study of various modalities in the treatment of keloids. Int J Dermatol 57(10):1192–1200PubMedCrossRef
13.
Zurück zum Zitat Shaarawy E, Hegazy RA, Abdel Hay RM (2015) Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol 14(2):161–166PubMedCrossRef Shaarawy E, Hegazy RA, Abdel Hay RM (2015) Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol 14(2):161–166PubMedCrossRef
14.
Zurück zum Zitat Ahuja RB, Chatterjee P (2014) Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns 40(4):583–588PubMedCrossRef Ahuja RB, Chatterjee P (2014) Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns 40(4):583–588PubMedCrossRef
15.
Zurück zum Zitat Srivastava S, Kumari H, Singh A (2019) Comparison of fractional CO2 Laser, verapamil, and triamcinolone for the treatment of keloid. Adv Wound Care (New Rochelle) 8(1):7–13CrossRef Srivastava S, Kumari H, Singh A (2019) Comparison of fractional CO2 Laser, verapamil, and triamcinolone for the treatment of keloid. Adv Wound Care (New Rochelle) 8(1):7–13CrossRef
16.
Zurück zum Zitat Chunan Qu, Min Li, Dongyue Li et al (2018) Comparison between verapamil and triamcinolone injection in the treatment of keloid. Chin J Aesthet Plast Surg 06:366–368 Chunan Qu, Min Li, Dongyue Li et al (2018) Comparison between verapamil and triamcinolone injection in the treatment of keloid. Chin J Aesthet Plast Surg 06:366–368
17.
Zurück zum Zitat Saha AK, Mukhopadhyay M (2012) A comparative clinical study on role of 5-flurouracil versus triamcinolone in the treatment of keloids. Indian J Surg 74(4):326–329PubMedPubMedCentralCrossRef Saha AK, Mukhopadhyay M (2012) A comparative clinical study on role of 5-flurouracil versus triamcinolone in the treatment of keloids. Indian J Surg 74(4):326–329PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Khalid FA, Mehrose MY, Saleem M et al (2019) Comparison of efficacy and safety of intralesional triamcinolone and combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: randomised control trial. Burns 45(1):69–75PubMedCrossRef Khalid FA, Mehrose MY, Saleem M et al (2019) Comparison of efficacy and safety of intralesional triamcinolone and combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: randomised control trial. Burns 45(1):69–75PubMedCrossRef
19.
Zurück zum Zitat Sadeghinia A, Sadeghinia S (2012) Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. Dermatol Surg 38(1):104–109PubMedCrossRef Sadeghinia A, Sadeghinia S (2012) Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. Dermatol Surg 38(1):104–109PubMedCrossRef
20.
Zurück zum Zitat Chen XE, Liu J, Bin Jameel AA et al (2017) Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Exp Ther Med 13(6):3607–3612PubMedPubMedCentralCrossRef Chen XE, Liu J, Bin Jameel AA et al (2017) Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprospan and 5-fluorouracil in the treatment of keloid scars. Exp Ther Med 13(6):3607–3612PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Darougheh A, Asilian A, Shariati F (2009) Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 34(2):219–223PubMedCrossRef Darougheh A, Asilian A, Shariati F (2009) Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 34(2):219–223PubMedCrossRef
22.
Zurück zum Zitat Asilian A, Darougheh A, Shariati F (2006) New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg 32(7):907–915PubMed Asilian A, Darougheh A, Shariati F (2006) New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg 32(7):907–915PubMed
23.
Zurück zum Zitat Khan MA, Bashir MM, Khan FA (2014) Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. J Pak Med Assoc 64(9):1003–1007PubMed Khan MA, Bashir MM, Khan FA (2014) Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. J Pak Med Assoc 64(9):1003–1007PubMed
24.
Zurück zum Zitat Hietanen KE, Järvinen TA, Huhtala H et al (2019) Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections-a randomized controlled trial. J Plast Reconstr Aesthet Surg 72(1):4–11PubMedCrossRef Hietanen KE, Järvinen TA, Huhtala H et al (2019) Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections-a randomized controlled trial. J Plast Reconstr Aesthet Surg 72(1):4–11PubMedCrossRef
25.
Zurück zum Zitat Manuskiatti W, Fitzpatrick RE (2002) Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 138(9):1149–1155PubMedCrossRef Manuskiatti W, Fitzpatrick RE (2002) Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 138(9):1149–1155PubMedCrossRef
26.
Zurück zum Zitat Abedini R, Sasani P, Mahmoudi HR et al (2018) Comparison of intralesional verapamil versus intralesional corticosteroids in treatment of keloids and hypertrophic scars: a randomized controlled trial. Burns 44(6):1482–1488PubMedCrossRef Abedini R, Sasani P, Mahmoudi HR et al (2018) Comparison of intralesional verapamil versus intralesional corticosteroids in treatment of keloids and hypertrophic scars: a randomized controlled trial. Burns 44(6):1482–1488PubMedCrossRef
27.
Zurück zum Zitat Margaret Shanthi FX, Ernest K, Dhanraj P (2008) Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 74(4):343–348PubMedCrossRef Margaret Shanthi FX, Ernest K, Dhanraj P (2008) Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 74(4):343–348PubMedCrossRef
28.
Zurück zum Zitat Bilal Muhammad, Tahmeedullah Irfanullah et al (2013) Clinical outcome of intralesional corticosteroid versus intralesional Verapamil in the treatment of post burn Keloid scars of the head and neck region. Pak J Surg 29(4):263–268 Bilal Muhammad, Tahmeedullah Irfanullah et al (2013) Clinical outcome of intralesional corticosteroid versus intralesional Verapamil in the treatment of post burn Keloid scars of the head and neck region. Pak J Surg 29(4):263–268
30.
Zurück zum Zitat Fanous A, Bezdjian A, Caglar D et al (2019) Treatment of keloid scars with botulinum toxin type A versus triamcinolone in an athymic nude mouse model. Plast Reconstr Surg 143(3):760–767PubMedCrossRef Fanous A, Bezdjian A, Caglar D et al (2019) Treatment of keloid scars with botulinum toxin type A versus triamcinolone in an athymic nude mouse model. Plast Reconstr Surg 143(3):760–767PubMedCrossRef
31.
Zurück zum Zitat Gassner HG, Sherris DA, Otley CC (2000) Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 105(6):1948–1953PubMedCrossRef Gassner HG, Sherris DA, Otley CC (2000) Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 105(6):1948–1953PubMedCrossRef
32.
Zurück zum Zitat Prodromidou A, Frountzas M, Vlachos DE et al (2015) Botulinum toxin for the prevention and healing of wound scars: a systematic review of the literature. Plast Surg (Oakv) 23(4):260–264CrossRef Prodromidou A, Frountzas M, Vlachos DE et al (2015) Botulinum toxin for the prevention and healing of wound scars: a systematic review of the literature. Plast Surg (Oakv) 23(4):260–264CrossRef
34.
Zurück zum Zitat Jagdeo J, Carruthers A, Smith KC (2015) New frontiers and clinical applications for botulinum neuromodulators. Dermatol Surg 41(Suppl 1):S17–S18PubMedCrossRef Jagdeo J, Carruthers A, Smith KC (2015) New frontiers and clinical applications for botulinum neuromodulators. Dermatol Surg 41(Suppl 1):S17–S18PubMedCrossRef
35.
Zurück zum Zitat Qu C, Liu Y, Wang X et al (2017) New progress in the treatment of pathological scar. Chin J Aesthet Plast Surg 10:639–640 Qu C, Liu Y, Wang X et al (2017) New progress in the treatment of pathological scar. Chin J Aesthet Plast Surg 10:639–640
36.
Zurück zum Zitat Xu SJ, Teng JY, Xie J et al (2009) Comparison of the mechanisms of intralesional steroid, interferon or verapamil injection in the treatment of proliferative scars. Zhonghua Zheng Xing Wai Ke Za Zhi 25(1):37–40PubMed Xu SJ, Teng JY, Xie J et al (2009) Comparison of the mechanisms of intralesional steroid, interferon or verapamil injection in the treatment of proliferative scars. Zhonghua Zheng Xing Wai Ke Za Zhi 25(1):37–40PubMed
37.
Zurück zum Zitat Robles DT, Moore E, Draznin M et al (2007) Keloids: pathophysiology and management. Dermatol Online J 13(3):9PubMed Robles DT, Moore E, Draznin M et al (2007) Keloids: pathophysiology and management. Dermatol Online J 13(3):9PubMed
38.
Zurück zum Zitat Wang R, Mao Y, Zhang Z et al (2016) Role of verapamil in preventing and treating hypertrophic scars and keloids. Int Wound J 13(4):461–468PubMedCrossRef Wang R, Mao Y, Zhang Z et al (2016) Role of verapamil in preventing and treating hypertrophic scars and keloids. Int Wound J 13(4):461–468PubMedCrossRef
39.
Zurück zum Zitat Giugliano G, Pasquali D, Notaro A et al (2003) Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts. Br J Plast Surg 56(8):804–809PubMedCrossRef Giugliano G, Pasquali D, Notaro A et al (2003) Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts. Br J Plast Surg 56(8):804–809PubMedCrossRef
40.
Zurück zum Zitat Blumenkranz MS, Claflin A, Hajek AS (1984) Selection of therapeutic agents for intraocular proliferative disease. Cell culture evaluation. Arch Ophthalmol 102(4):598–604PubMedCrossRef Blumenkranz MS, Claflin A, Hajek AS (1984) Selection of therapeutic agents for intraocular proliferative disease. Cell culture evaluation. Arch Ophthalmol 102(4):598–604PubMedCrossRef
41.
Zurück zum Zitat Fitzpatrick RE (1999) Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg 25(3):224–232PubMedCrossRef Fitzpatrick RE (1999) Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg 25(3):224–232PubMedCrossRef
42.
Zurück zum Zitat Shah VV, Aldahan AS, Mlacker S et al (2016) 5-fluorouracil in the treatment of keloids and hypertrophic scars: a comprehensive review of the literature. Dermatol Ther (Heidelb) 6(2):169–183CrossRef Shah VV, Aldahan AS, Mlacker S et al (2016) 5-fluorouracil in the treatment of keloids and hypertrophic scars: a comprehensive review of the literature. Dermatol Ther (Heidelb) 6(2):169–183CrossRef
Metadaten
Titel
The Efficacy of Drug Injection in the Treatment of Pathological Scar: A Network Meta-analysis
verfasst von
Pengfei Sun
Xiaosheng Lu
Huachang Zhang
Zhensheng Hu
Publikationsdatum
18.12.2019
Verlag
Springer US
Erschienen in
Aesthetic Plastic Surgery / Ausgabe 2/2021
Print ISSN: 0364-216X
Elektronische ISSN: 1432-5241
DOI
https://doi.org/10.1007/s00266-019-01570-8

Weitere Artikel der Ausgabe 2/2021

Aesthetic Plastic Surgery 2/2021 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.